Gemcitabine (G) followed by 2nd line Docetaxel (D) is feasible in advanced NSCLC: Results from a randomized phase II study
- 30 September 2000
- journal article
- abstracts
- Published by Elsevier in Lung Cancer
- Vol. 29 (1) , 11-12
- https://doi.org/10.1016/s0169-5002(00)80032-x
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: